Unknown

Dataset Information

0

CTLA4-Ig in combination with FTY720 promotes allograft survival in sensitized recipients.


ABSTRACT: Despite recent evidence of improved graft outcomes and safety, the high incidence of early acute cellular rejection with belatacept, a high-affinity CTLA4-Ig, has limited its use in clinical transplantation. Here we define how the incomplete control of endogenous donor-reactive memory T cells results in belatacept-resistant rejection in an experimental model of BALB/c.2W-OVA donor heart transplantation into C57BL/6 recipients presensitized to donor splenocytes. These sensitized mice harbored modestly elevated numbers of endogenous donor-specific memory T cells and alloantibodies compared with naive recipients. Continuous CTLA4-Ig treatment was unexpectedly efficacious at inhibiting endogenous graft-reactive T cell expansion but was unable to inhibit late CD4+ and CD8+ T cell infiltration into the allografts, and rejection was observed in 50% of recipients by day 35 after transplantation. When CTLA4-Ig was combined with the sphingosine 1-phosphate receptor-1 (S1PR1) functional antagonist FTY720, alloantibody production was inhibited and donor-specific IFN-?-producing T cells were reduced to levels approaching nonsensitized tolerant recipients. Late T cell recruitment into the graft was also restrained, and graft survival improved with this combination therapy. These observations suggest that a rational strategy consisting of inhibiting memory T cell expansion and trafficking into the allograft with CTLA4-Ig and FTY720 can promote allograft survival in allosensitized recipients.

SUBMITTER: Khiew SH 

PROVIDER: S-EPMC5414557 | biostudies-other | 2017 May

REPOSITORIES: biostudies-other

altmetric image

Publications

CTLA4-Ig in combination with FTY720 promotes allograft survival in sensitized recipients.

Khiew Stella H SH   Yang Jinghui J   Young James S JS   Chen Jianjun J   Wang Qiang Q   Yin Dengping D   Vu Vinh V   Miller Michelle L ML   Sciammas Roger R   Alegre Maria-Luisa ML   Chong Anita S AS  

JCI insight 20170504 9


Despite recent evidence of improved graft outcomes and safety, the high incidence of early acute cellular rejection with belatacept, a high-affinity CTLA4-Ig, has limited its use in clinical transplantation. Here we define how the incomplete control of endogenous donor-reactive memory T cells results in belatacept-resistant rejection in an experimental model of BALB/c.2W-OVA donor heart transplantation into C57BL/6 recipients presensitized to donor splenocytes. These sensitized mice harbored mod  ...[more]

Similar Datasets

| S-EPMC4610858 | biostudies-literature
| S-EPMC3848405 | biostudies-other
| S-EPMC6593256 | biostudies-literature
| S-EPMC11336573 | biostudies-literature
| S-EPMC5399033 | biostudies-literature
| S-EPMC8484495 | biostudies-literature
| S-EPMC8443599 | biostudies-literature
| S-EPMC3594012 | biostudies-literature
| S-EPMC9773869 | biostudies-literature
| S-EPMC2772128 | biostudies-literature